Quarry LP Grows Position in West Pharmaceutical Services, Inc. (NYSE:WST)

Quarry LP increased its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 155.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 97 shares of the medical instruments supplier’s stock after purchasing an additional 59 shares during the quarter. Quarry LP’s holdings in West Pharmaceutical Services were worth $34,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Planned Solutions Inc. acquired a new stake in West Pharmaceutical Services in the 4th quarter valued at approximately $39,000. Addison Advisors LLC raised its holdings in shares of West Pharmaceutical Services by 28.9% in the 4th quarter. Addison Advisors LLC now owns 183 shares of the medical instruments supplier’s stock valued at $64,000 after buying an additional 41 shares during the period. Livforsakringsbolaget Skandia Omsesidigt lifted its stake in West Pharmaceutical Services by 90.0% during the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 190 shares of the medical instruments supplier’s stock worth $67,000 after acquiring an additional 90 shares in the last quarter. Lindbrook Capital LLC boosted its holdings in West Pharmaceutical Services by 46.0% during the 4th quarter. Lindbrook Capital LLC now owns 235 shares of the medical instruments supplier’s stock valued at $83,000 after acquiring an additional 74 shares during the period. Finally, Tompkins Financial Corp acquired a new position in West Pharmaceutical Services in the 4th quarter valued at about $89,000. 93.90% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at West Pharmaceutical Services

In other news, SVP Silji Abraham sold 1,800 shares of the business’s stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $330.78, for a total transaction of $595,404.00. Following the completion of the transaction, the senior vice president now directly owns 2,860 shares of the company’s stock, valued at $946,030.80. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other news, CEO Eric Mark Green sold 66,000 shares of the company’s stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $366.65, for a total transaction of $24,198,900.00. Following the completion of the transaction, the chief executive officer now directly owns 152,908 shares of the company’s stock, valued at approximately $56,063,718.20. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Silji Abraham sold 1,800 shares of the stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $330.78, for a total value of $595,404.00. Following the completion of the transaction, the senior vice president now owns 2,860 shares in the company, valued at approximately $946,030.80. The disclosure for this sale can be found here. 0.53% of the stock is owned by corporate insiders.

West Pharmaceutical Services Stock Up 0.9 %

Shares of NYSE:WST opened at $336.10 on Tuesday. The firm’s 50-day moving average is $353.78 and its two-hundred day moving average is $361.97. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.61 and a quick ratio of 1.95. West Pharmaceutical Services, Inc. has a 1 year low of $310.42 and a 1 year high of $415.73. The firm has a market capitalization of $24.48 billion, a PE ratio of 44.34, a price-to-earnings-growth ratio of 5.88 and a beta of 1.01.

West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, April 25th. The medical instruments supplier reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.29 by $0.27. The firm had revenue of $695.40 million for the quarter, compared to the consensus estimate of $670.62 million. West Pharmaceutical Services had a net margin of 19.42% and a return on equity of 20.57%. The firm’s revenue for the quarter was down 3.0% on a year-over-year basis. During the same period in the prior year, the firm earned $1.98 EPS. Analysts predict that West Pharmaceutical Services, Inc. will post 7.76 EPS for the current year.

West Pharmaceutical Services Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, August 7th. Shareholders of record on Wednesday, July 31st will be issued a dividend of $0.20 per share. The ex-dividend date is Wednesday, July 31st. This represents a $0.80 annualized dividend and a yield of 0.24%. West Pharmaceutical Services’s dividend payout ratio (DPR) is 10.55%.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.